Leukemia - Table of Contents alert Volume 32 Issue 3

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 32, Issue 3 (March 2018) In this issue Original Articles Letters to the Editor Also new AOP   Sign up for e-alerts Recommend to your library Web feed Subscribe Original Articles Acute myeloid leukemia Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion B Kumar, M Garcia, L Weng, X Jung, J L Murakami et al. Leukemia 2017 32 :575 - 587; August 17, 2017; 10.1038/leu.2017.259   Abstract | Full Text Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner P Peña-Martínez, M Eriksson, R Ramakrishnan, M Chapellier, C Högberg et al. Leukemia 2017 32 :588 - 596; August 18, 2017; 10.1038/leu.2017.261   Abstract | Full Text RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia M-A Hospital, A Jacquel, F Mazed, E Saland, C Larrue et al. Leukemia 2017 32 :597 - 605; September 15, 2017; 10.1038/leu.2017.284   Abstract | Full Text Acute lymphoblastic leukemia Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia N Toft, H Birgens, J Abrahamsson, L Griškevicius, H Hallböök et al. Leukemia 2017 32 :606 - 615; August 18, 2017; 10.1038/leu.2017.265   Abstract | Full Text Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia S Takao, W Chien, V Madan, D-C Lin, L-W Ding et al. Leukemia 2017 32 :616 - 625; September 14, 2017; 10.1038/leu.2017.281   Abstract | Full Text High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG T Sakura, F Hayakawa, I Sugiura, T Murayama, K Imai et al. Leukemia 2017 32 :626 - 632; September 15, 2017; 10.1038/leu.2017.283   Abstract | Full Text NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL C Prieto, B López-Millán, H Roca-Ho, R W Stam, D Romero-Moya et al. Leukemia 2017 32 :633 - 644; September 25, 2017; 10.1038/leu.2017.294   Abstract | Full Text Chronic lymphocytic leukemia Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia F Nadeu, G Clot, J Delgado, D Martín-García, T Baumann et al. Leukemia 2017 32 :645 - 653; September 19, 2017; 10.1038/leu.2017.291   Abstract | Full Text NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-?B pathways D Benedetti, E Tissino, F Pozzo, T Bittolo, C Caldana et al. Leukemia 2017 32 :654 - 662; September 22, 2017; 10.1038/leu.2017.296   Abstract | Full Text Lymphoma Targeting nucleolin for better survival in diffuse large B-cell lymphoma N Jain, H Zhu, T Khashab, Q Ye, B George et al. Leukemia 2017 32 :663 - 674; July 10, 2017; 10.1038/leu.2017.215   Abstract | Full Text Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets K Karube, A Enjuanes, I Dlouhy, P Jares, D Martin-Garcia et al. Leukemia 2017 32 :675 - 684; August 14, 2017; 10.1038/leu.2017.251   Abstract | Full Text Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing A Zamò, J Pischimarov, M Schlesner, P Rosenstiel, R Bomben et al. Leukemia 2017 32 :685 - 693; August 21, 2017; 10.1038/leu.2017.270   Abstract | Full Text Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma M Fujisawa, M Sakata-Yanagimoto, S Nishizawa, D Komori, P Gershon et al. Leukemia 2017 32 :694 - 702; August 23, 2017; 10.1038/leu.2017.273   Abstract | Full Text HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma Y J Jia, Z B Liu, W G Wang, C B Sun, P Wei et al. Leukemia 2017 32 :703 - 711; September 28, 2017; 10.1038/leu.2017.299   Abstract | Full Text Multiple myeloma, gammopathies Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation R Chakraborty, E Muchtar, S K Kumar, F K Buadi, D Dingli et al. Leukemia 2017 32 :712 - 718; August 14, 2017; 10.1038/leu.2017.256   Abstract | Full Text Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial S Ailawadhi, J R Mikhael, B R LaPlant, K M Laumann, S Kumar et al. Leukemia 2017 32 :719 - 728; September 01, 2017; 10.1038/leu.2017.258   Abstract | Full Text Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains S Sidana, N Tandon, A Dispenzieri, M A Gertz, F K Buadi et al. Leukemia 2017 32 :729 - 735; September 18, 2017; 10.1038/leu.2017.286   Abstract | Full Text JAM-A as a prognostic factor and new therapeutic target in multiple myeloma A G Solimando, A Brandl, K Mattenheimer, C Graf, M Ritz et al. Leukemia 2017 32 :736 - 743; September 28, 2017; 10.1038/leu.2017.287   Abstract | Full Text 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors Y Gu, K Xu, C Torre, M Samur, B G Barwick et al. Leukemia 2017 32 :744 - 751; September 19, 2017; 10.1038/leu.2017.288   Abstract | Full Text Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma J Bae, T Hideshima, G L Zhang, J Zhou, D B Keskin et al. Leukemia 2017 32 :752 - 764; November 01, 2017; 10.1038/leu.2017.316   Abstract | Full Text Stem cell transplantation Extracellular vesicles as potential biomarkers of acute graft-vs-host disease G Lia, L Brunello, S Bruno, A Carpanetto, P Omedè et al. Leukemia 2017 32 :765 - 773; August 30, 2017; 10.1038/leu.2017.277   Abstract | Full Text Molecular targets for therapy Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling E I Andersson, S Pützer, B Yadav, O Dufva, S Khan et al. Leukemia 2017 32 :774 - 787; August 14, 2017; 10.1038/leu.2017.252   Abstract | Full Text Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia S Degryse, C E de Bock, S Demeyer, I Govaerts, S Bornschein et al. Leukemia 2017 32 :788 - 800; August 30, 2017; 10.1038/leu.2017.276   Abstract | Full Text Immunotherapy Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells Y Lai, J Weng, X Wei, L Qin, P Lai et al. Leukemia 2017 32 :801 - 808; August 03, 2017; 10.1038/leu.2017.249   Abstract | Full Text Transcriptional control and signal transduction, cell cycle The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling T Girardi, S Vereecke, S O Sulima, Y Khan, L Fancello et al. Leukemia 2017 32 :809 - 819; July 24, 2017; 10.1038/leu.2017.225   Abstract | Full Text Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis S Gerboth, E Frittoli, A Palamidessi, F C Baltanas, M Salek et al. Leukemia 2017 32 :820 - 827; August 18, 2017; 10.1038/leu.2017.267   Abstract | Full Text C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation A E Marneth, K H M Prange, A S A Al Hinai, S M Bergevoet, N Tesi et al. Leukemia 2017 32 :828 - 836; September 05, 2017; 10.1038/leu.2017.280   Abstract | Full Text Letters to the Editor Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis A Tefferi, T L Lasho, C Finke, N Gangat, C A Hanson et al. Leukemia 2017 32 :837 - 839; November 01, 2017; 10.1038/leu.2017.318   Abstract | Full Text A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia H Sakai, N Hosono, H Nakazawa, B Przychodzen, C Polprasert et al. Leukemia 2017 32 :839 - 843; November 03, 2017; 10.1038/leu.2017.319   Abstract | Full Text Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma A Ray, D S Das, Y Song, T Hideshima, Y-T Tai et al. Leukemia 2017 32 :843 - 846; November 06, 2017; 10.1038/leu.2017.322   Abstract | Full Text Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia S C Nimmagadda, S Frey, B Edelmann, C Hellmich, L Zaitseva et al. Leukemia 2017 32 :846 - 849; November 07, 2017; 10.1038/leu.2017.324   Abstract | Full Text Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53 S Chen, R Gao, C Yao, M Kobayashi, S Z Liu et al. Leukemia 2017 32 :850 - 854; November 16, 2017; 10.1038/leu.2017.325   Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.